BRIEF—Halozyme withdraws non-binding offer for Evotec

Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash.

The management and supervisory boards of Evotec, together with its advisors, have been in the process of thoroughly assessing the non-binding proposal submitted by Halozyme in a letter dated November 23, 2024, in which it expressed an interest in a combination of Halozyme with Evotec.

Both Evotec boards continue to have strong conviction in the company’s standalone strategy, which is expected to accelerate growth, strengthen the long-term profitability of the company and deliver significant value to shareholders.